According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

Learn more about whether SoundHound AI, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Vertex Pharmaceuticals has multiple growth drivers with potentially more on the way. Yo-yos are fun for kids. But yo-yo stock ...

Vertex’s stock price has shown remarkable growth ... on revenue of $175.0 million to $178.0 million. InvestingPro analysis reveals the company maintains a healthy financial profile with an ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

Vertex: Financial Performance Dissected Market Capitalization Analysis: The company's market ... Typically, analysts will rate each stock once a quarter. Some analysts publish their predictions ...

Vertex Software's stock has fallen ~30% since January due to a valuation correction and market pessimism over slowing growth rates. Despite the selloff, Vertex's valuation multiples haven't ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex’s stock price has shown remarkable growth ... of $33.0 million to $37.0 million on revenue of $175.0 million to $178.0 million. InvestingPro analysis reveals the company maintains a healthy ...